Government Briefs: White House Moves On Patent Reform, DOJ Settles Endo Off-Label Complaints
Executive Summary
Endo admits to marketing its post-herpetic neuralgia pain drug Lidoderm for unapproved uses in a $192.7 million settlement; National Economic Council Director says there is “a sweet spot for bipartisan compromise” on patent troll bills introduced in the House and Senate.
You may also be interested in...
Pharma Deals With The DOJ
A look at the settlement agreements pharma companies have struck with the Department of Justice in the last three years; the size of the deals has declined dramatically since 2012.
Patent Troll Bill Clears House; Provisions Problematic For PhRMA Remain
Amendments make things a little better for drug firms as attention now shifts to the Senate version.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.